Wall Street analysts expect that Envista Holdings Co. (NYSE:NVST – Get Rating) will announce sales of $627.29 million for the current fiscal quarter, according to Zacks Investment Research. Six analysts have made estimates for Envista’s earnings. The lowest sales estimate is $611.20 million and the highest is $636.80 million. Envista reported sales of $709.20 million during the same quarter last year, which indicates a negative year over year growth rate of 11.5%. The company is expected to announce its next earnings report after the market closes on Monday, January 1st.
According to Zacks, analysts expect that Envista will report full year sales of $2.64 billion for the current financial year, with estimates ranging from $2.60 billion to $2.66 billion. For the next financial year, analysts expect that the business will post sales of $2.85 billion, with estimates ranging from $2.82 billion to $2.90 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Envista.
Envista (NYSE:NVST – Get Rating) last posted its quarterly earnings results on Wednesday, February 9th. The company reported $0.46 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.42 by $0.04. Envista had a return on equity of 8.96% and a net margin of 12.57%. The firm had revenue of $651.80 million during the quarter, compared to the consensus estimate of $633.22 million. During the same quarter in the previous year, the business earned $0.56 earnings per share.
In other Envista news, CFO Howard H. Yu sold 5,341 shares of the company’s stock in a transaction that occurred on Monday, April 18th. The stock was sold at an average price of $45.73, for a total transaction of $244,243.93. Following the sale, the chief financial officer now owns 52,411 shares in the company, valued at $2,396,755.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Mischa Reis sold 6,056 shares of the company’s stock in a transaction that occurred on Friday, February 11th. The shares were sold at an average price of $47.50, for a total value of $287,660.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 160,829 shares of company stock worth $7,852,658. Insiders own 0.82% of the company’s stock.
Several large investors have recently bought and sold shares of NVST. First Horizon Advisors Inc. grew its holdings in shares of Envista by 357.5% during the third quarter. First Horizon Advisors Inc. now owns 398 shares of the company’s stock valued at $34,000 after purchasing an additional 311 shares during the last quarter. Dark Forest Capital Management LP grew its holdings in shares of Envista by 69.1% during the third quarter. Dark Forest Capital Management LP now owns 947 shares of the company’s stock valued at $40,000 after purchasing an additional 387 shares during the last quarter. Covestor Ltd bought a new position in Envista in the 4th quarter worth approximately $43,000. Eagle Bay Advisors LLC grew its holdings in Envista by 100.0% in the 3rd quarter. Eagle Bay Advisors LLC now owns 1,800 shares of the company’s stock worth $76,000 after buying an additional 900 shares in the last quarter. Finally, CWM LLC bought a new position in Envista in the 4th quarter worth approximately $84,000.
Shares of NYSE NVST opened at $45.34 on Thursday. Envista has a 1-year low of $37.60 and a 1-year high of $52.03. The business has a 50-day moving average of $47.47 and a 200-day moving average of $43.94. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.52 and a quick ratio of 1.30. The company has a market capitalization of $7.37 billion, a price-to-earnings ratio of 23.61, a PEG ratio of 1.75 and a beta of 1.59.
About Envista (Get Rating)
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, and markets dental products in the United States and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Logon, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Ormco, Insignia, AOA, and Spark brands.
Recommended Stories
- Get a free copy of the StockNews.com research report on Envista (NVST)
- Highly Valued Abbot Laboratories Could Move Lower
- Baker Hughes, Another Buy-The-Dip Opportunity In Oilfield Services
- Netflix (NASDAQ: NFLX) Falls Back to 2018 Levels
- Is Turning Point Therapeutics Stock at a Turning Point?
- Buy Haliburton On Post-Earnings Weakness
Get a free copy of the Zacks research report on Envista (NVST)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.